Loading…
Hosted by The Lancet Infectious Diseases · EN-UK · 125 episodes
Established thought leaders with verified media credentials.
The Lancet Infectious Diseases is a monthly journal, renowned for the publication of high-quality peer-reviewed reviews and analysis from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue.
The Lancet Infectious Diseases hosts Listen to The Lancet Infectious Diseases, a science show with 125 episodes published.
Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberc
Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbr
Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clin
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them.
Series authors discuss their papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape.
Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of
Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implication
Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They di
Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implicatio
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue
Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the tri
Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Braz
Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia.
Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong.
Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021.
Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhoo
A new Article in The Lancet Infectious Diseases highlights how changing immunity profiles motivate the need for better responses to outbreaks of polio in Africa.
Paul Chapman and colleagues presents the results of an innovative trial assessing the safety of vaccinating healthy volunteers with attenuated Necator americanus hookworm larvae.
Josep Llibre discusses a trial on the impact of same-day testing for SARS-CoV-2 infection before a concert on new COVID-19 cases in Ba rcelona, Spain.
Yap Boum (MSF) discusses his study done in Cameroon, which developed a promising testing strategy for COVID-19 to optimise the available resource.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Listen to The Lancet Infectious Diseases has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Listen to The Lancet Infectious Diseases is hosted by The Lancet Infectious Diseases. The show is categorised under science (medicine) and has published 125 episodes.
Listen to The Lancet Infectious Diseases has published 125 episodes.
Listen to The Lancet Infectious Diseases regularly covers science, medicine, health. It sits in the science category, with a medicine focus.
Listen to The Lancet Infectious Diseases is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Listen to The Lancet Infectious Diseases hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Listen to The Lancet Infectious Diseases average 21 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Listen to The Lancet Infectious Diseases's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched yesterday.